Alyeska Investment Group
MAZE

Alyeska Investment Group’s Maze Therapeutics MAZE Stock Holding History

Alyeska Investment Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98M Hold
100,000
– – 0.01% 546
2026
Q1 		$2.98M Sell
100,000
-96,124
-49% -$4.24M 0.01% 527
2025
Q4 		$8.13M Buy
196,124
+71,124
+57% +$2.44M 0.02% 415
2025
Q3 		$3.24M Hold
125,000
– – 0.01% 486
2025
Q2 		$1.53M Hold
125,000
– – 0.01% 487
2025
Q1 		$1.38M Buy
+125,000
New +$1.5M 0.01% 429

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Alyeska Investment Group's MAZE Position: Q2 2026 in Review

Alyeska Investment Group held its Maze Therapeutics (MAZE) position steady in Q2 2026 at 100,000 shares worth $2.98M. The position accounts for 0.01% of the portfolio, ranked #546.

Alyeska Investment Group first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $8.13M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Alyeska Investment Group held 100,000 shares of Maze Therapeutics worth $2.98M as of Q2 2026.
  • Alyeska Investment Group left its Maze Therapeutics share count unchanged in Q2 2026.
  • Maze Therapeutics made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #546 holding.
  • Alyeska Investment Group first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Alyeska Investment Group's Maze Therapeutics position peaked at $8.13M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.